UniPharma Co., Ltd. (TPEX:6621)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.00
-0.30 (-2.44%)
Feb 11, 2026, 2:57 PM CST

UniPharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-38.84-24.82-21.81-6.45-74.41-55.35
Depreciation & Amortization
7.016.985.535.4810.7211.11
Other Amortization
0.040.020.020.050.060.06
Loss (Gain) From Sale of Assets
0.050.04--10.71--1.77
Asset Writedown & Restructuring Costs
----36.4339.05
Stock-Based Compensation
---0.46--
Other Operating Activities
----0.58-0.01-
Change in Accounts Receivable
3.54.110.24-9.912.410.8
Change in Inventory
-3.616.672.14.89-10.280.32
Change in Accounts Payable
13.4-7.7716.15-21.5625.44-8.31
Change in Unearned Revenue
-0-0.15-0.40.71-0.14-2.63
Change in Other Net Operating Assets
-0.70.610.25.96-3.15-0.47
Operating Cash Flow
-19.15-14.3212.03-31.65-12.93-17.18
Capital Expenditures
-1.14-0.79-8.11-0.44-0.61-0.53
Sale of Property, Plant & Equipment
---0.05-2.26
Divestitures
---3.32--
Sale (Purchase) of Intangibles
-2.05-2.05---2.6-0.11
Investment in Securities
32.819.243.53-625.5529.89
Other Investing Activities
0.111.780.691.95-2.550.35
Investing Cash Flow
29.738.18-3.89-1.1219.831.85
Long-Term Debt Repaid
--3.55-3.26-3.43-5.49-5.63
Net Debt Issued (Repaid)
-3.68-3.55-3.26-3.43-5.49-5.63
Issuance of Common Stock
---3--
Other Financing Activities
--0.29-21-0.06
Financing Cash Flow
-3.68-3.83-3.2620.57-5.49-5.57
Net Cash Flow
6.9-9.974.89-12.21.379.11
Free Cash Flow
-20.29-15.113.92-32.09-13.54-17.71
Free Cash Flow Margin
-22.35%-16.17%3.80%-25.05%-12.85%-12.78%
Free Cash Flow Per Share
-0.57-0.430.11-0.90-0.39-0.50
Cash Interest Paid
0.10.10.010.040.10.14
Levered Free Cash Flow
-3.25-6.338.63-15.42-26.34-12.72
Unlevered Free Cash Flow
-3.18-6.268.64-15.4-26.28-12.63
Change in Working Capital
12.593.4628.3-19.9114.27-10.28
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.